We have successfully applied our conjugation technologies for optimising pharmacokinetics and pharmacodynamics to a wide range of novel and established therapeutic proteins, including antibody fragments, enzymes, blood factors, cytokines, novel protein scaffolds, and peptides. We have also applied our technologies to produce better antibody drug conjugates (ADCs) using whole antibodies, novel antibody formats and antibody fragments and have access, via our partners, to a range of cytotoxic drugs with different mechanisms of action.
In addition to in-house conjugation, our scientists have expertise in designing and managing in vivo pharmacokinetic, pharmacodynamic and xenograft studies and these can be set-up and managed on your behalf.
We collaborate with a wide range of organisations from virtual companies through to big pharma, including many of the world’s top companies, as well as academic research groups from across the globe.
PolyTherics is part of the Abzena group of companies.